Distributing since 1889 • Employee Owned for Better Service

Your 1st Choice!

Quick Search:

Cart | My Account | View Printable Page

Product Detail

NOTICE: This is the ProQuest Ebook Centralï¿½ format of this title. What is ProQuest Ebook Centralï¿½?

Other formats:

Hardcover

All Formats

Development of Antibody-Based Therapeutics: Translational Considerations

Tabrizi, Mohammad A.

Pricing & Availability
Available: Yes*
This title does not qualify for any discount.

Email this title to a friend

Printer friendly version

Other formats:

Book Information
Edition:	1st
Publisher:	Springer
ISBN:	1-4419-5955-6 (1441959556)
ISBN-13:	978-1-4419-5955-3 (9781441959553)
Binding:	E E Book + ProQuest Ebook Central
Copyright:	2012
Publish Date:	06/12
Weight:	0.00 Lbs.
Subject Class:	RET (Returns)
Remarks:	A New Edition of this Title is Available
Return Policy:	Non-Returnable.
Table Of Contents:	View

ProQuest Ebook Centralï¿½:	Please sign in to preview this title

Class Specifications

Abstract:

Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the .unit dose' and .unit effect' with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in "relevant" animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies. This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics.

* Subject to ProQuest Ebook Centralï¿½ availability

Follow Matthews Book Co. on: